{"id":9425,"date":"2020-05-26T19:41:43","date_gmt":"2020-05-26T14:11:43","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9425"},"modified":"2023-02-10T11:49:16","modified_gmt":"2023-02-10T06:19:16","slug":"recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical","title":{"rendered":"Algernon&#8217;s NP-120; FDA nod to 4DMedical tool; SaNOtize&#8217;s NORSTM trial; Pole&#8217;s capital increase"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0a9ee6cb625\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0a9ee6cb625\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical\/#Algernon_Pharmaceuticals_has_announced_the_submission_of_an_Investigational_New_Drug_IND_application_of_its_drug_NP-120_for_COVID-19\" >Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19.&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical\/#4DMedical_has_received_the_FDA_recommendation_for_its_XV_Technology_a_respiratory_diagnostic_tool_for_lung_illnesses_amidst_COVID-19\" >4DMedical has received the FDA recommendation for its XV Technology, a respiratory diagnostic tool for lung illnesses amidst COVID-19.&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical\/#SaNOtize_Research_and_Development_Corporation_has_announced_the_start_of_multi-centre_Phase_II_trial_of_its_Nitric_Oxide_Releasing_Solution_NORSTM_for_preventing_COVID-19\" >SaNOtize Research and Development Corporation has announced the start of multi-centre Phase II trial of its Nitric Oxide Releasing Solution (NORSTM) for preventing COVID-19.&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical\/#Poxel_a_biopharmaceutical_company_devoted_to_making_innovative_treatments_for_metabolic_disease_has_successfully_raised_Euro_177_Million_in_a_capital_increase\" >Poxel, a biopharmaceutical company devoted to making innovative treatments for metabolic disease, has successfully raised Euro 17,7 Million in a capital increase.&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-algernon-pharmaceuticals-has-announced-the-submission-of-an-investigational-new-drug-ind-application-of-its-drug-np-120-for-covid-19\"><span class=\"ez-toc-section\" id=\"Algernon_Pharmaceuticals_has_announced_the_submission_of_an_Investigational_New_Drug_IND_application_of_its_drug_NP-120_for_COVID-19\"><\/span><strong>Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19.&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The company has submitted the IND with the US FDA for its planned multinational Phase 2b\/3 study of its repurposed drug NP-120 (Ifenprodil) for the treatment of patients suffering from <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19<\/a>. The drug &#8211; NP-120 \u2013 is an N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist and an orally delivered small molecule, originally developed by Sanofi and is approved to treat peripheral circulatory disorders.&nbsp;<\/p>\n\n\n\n<p>The clinical trial for the drug &#8211; A Randomized Open-Label Phase 2b\/3 Study of the Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Confirmed <a href=\"https:\/\/www.delveinsight.com\/blog\/realm-of-pandemics\">COVID-19<\/a> Infected Hospitalized Patients \u2013 for which Algernon has already received clearance in Canada and has also filed for ethics approval in Australia.<\/p>\n\n\n\n<p>The drug is believed to reduce the infiltration of neutrophils and T-cells into the lungs where they release glutamate and cytokines respectively, which result in cytokine storm that leads to the loss of <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-market\">lung <\/a>function and ultimately death as has been reported in <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">COVID-19<\/a> infected patients.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-4dmedical-has-received-the-fda-recommendation-for-its-xv-technology-a-respiratory-diagnostic-tool-for-lung-illnesses-amidst-covid-19\"><span class=\"ez-toc-section\" id=\"4DMedical_has_received_the_FDA_recommendation_for_its_XV_Technology_a_respiratory_diagnostic_tool_for_lung_illnesses_amidst_COVID-19\"><\/span><strong>4DMedical<\/strong> <strong>has received the FDA recommendation for its XV Technology, a respiratory diagnostic tool for lung illnesses amidst COVID-19.<\/strong>&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>4DMedical&#8217;s XV Technology is a software-as-a-service (SaaS) diagnostic tool, which is available through a secure cloud subscription and can be used by utilizing available infrastructure without any extra capital expenditure or training. Imaging departments simply electronically send an X-ray (using existing fluoroscopy equipment) to 4DMedical, and its ventilation reports will prove essential in providing quantitative support for diagnosis and follow up examinations for patients with or recovering from <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19<\/a>.<\/p>\n\n\n\n<p>The technology, company believes, would be beneficial to a patient suffering from lung disorders in the treatment of illnesses such as COVID-19, <a href=\"https:\/\/www.delveinsight.com\/report-store\/asthma-market\">asthma<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-market\">chronic obstructive pulmonary disease<\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/cystic-fibrosis-market\">cystic fibrosis<\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/small-cell-lung-cancer-market\">lung cancer<\/a>.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-sanotize-research-and-development-corporation-has-announced-the-start-of-multi-centre-phase-ii-trial-of-its-nitric-oxide-releasing-solution-norstm-for-preventing-covid-19\"><span class=\"ez-toc-section\" id=\"SaNOtize_Research_and_Development_Corporation_has_announced_the_start_of_multi-centre_Phase_II_trial_of_its_Nitric_Oxide_Releasing_Solution_NORSTM_for_preventing_COVID-19\"><\/span><strong>SaNOtize Research and Development Corporation has announced the start of multi-centre Phase II trial of its Nitric Oxide Releasing Solution (NORSTM) for preventing COVID-19.&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The company plans to enrol 210 individuals, including those who have either tested positive for <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\">COVID-19<\/a> or are at high risk of getting infected, such as front-line healthcare workers or caretakers of the patients.&nbsp;<\/p>\n\n\n\n<p>SaNOtize&#8217;s Nitric Oxide Releasing Solution (NORSTM) was able to inactivate more than 99.9% of <a href=\"https:\/\/www.delveinsight.com\/blog\/questions-and-answers-on-coronavirus-covid-19\">COVID-19<\/a> causing virus, SARs-CoV-2, within two minutes, in laboratory tests. The company is also testing nitric oxide (NO), a naturally occurring nano molecule, as a first-in-class drug as a topical antimicrobial agent to treat a wide variety of bacterial, viral and fungal diseases, including <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">COVID-19<\/a>.<\/p>\n\n\n\n<p>NORSTM has already received US and EU patents and is a testing ready-to-use, inexpensive and rapidly-scalable applications delivered through gargle solutions, nasal spray and nasal lavage.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-poxel-a-biopharmaceutical-company-devoted-to-making-innovative-treatments-for-metabolic-disease-has-successfully-raised-euro-17-7-million-in-a-capital-increase\"><span class=\"ez-toc-section\" id=\"Poxel_a_biopharmaceutical_company_devoted_to_making_innovative_treatments_for_metabolic_disease_has_successfully_raised_Euro_177_Million_in_a_capital_increase\"><\/span><strong>Poxel, a biopharmaceutical company devoted to making innovative treatments for metabolic disease, has successfully raised Euro 17,7 Million in a capital increase.&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Poxel is focused on developing therapies for metabolic diseases such as type 2 <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-foot-market\">diabetes <\/a>and <a href=\"https:\/\/www.delveinsight.com\/report-store\/nonalcoholic-steatohepatitis-nash-market\">non-alcoholic steatohepatitis (NASH)<\/a> and has three drug candidates in its armamentarium in mid-to-late stages of trials.&nbsp;<\/p>\n\n\n\n<p>The company plans to use the proceeds to advance the trials of its drug candidates into further phases of trials including PXL770 and PXL065 for the treatment of NASH. It awaits the results of PXL770 PK\/PD study and of an ongoing Phase 2a clinical trial as well as the to start the PXL065 Phase 2 study for the treatment of NASH. Moreover, Poxel is also planning to explore other metabolic diseases through AMPK activator and deuterated thiazolidinedione platforms. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19.&nbsp; The company has submitted the IND with the US FDA for its planned multinational Phase 2b\/3 study of its repurposed drug NP-120 (Ifenprodil) for the treatment of patients suffering from COVID-19. The drug &#8211; NP-120 \u2013 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9430,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[18383,18382,10830,12513,1394,349,1469,420,18384,639,1384,2023,18385],"industry":[17225],"therapeutic_areas":[17240,17231,17243],"class_list":["post-9425","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-4dmedical","tag-algernon-pharmaceuticals","tag-covid-19","tag-covid-19-news","tag-hepatitis-c","tag-latest-pharma-news","tag-nash","tag-news","tag-non-alcoholic-steatohepatitis","tag-pharma-news","tag-poxel","tag-type-2-diabetes","tag-ulcerative-colitis-treatment","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-infectious-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Algernon Pharma, 4DMedical, Poxel, SaNotize<\/title>\n<meta name=\"description\" content=\"Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19. The company has..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Algernon Pharma, 4DMedical, Poxel, SaNotize\" \/>\n<meta property=\"og:description\" content=\"Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19. The company has..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-05-26T14:11:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T06:19:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/26194923\/blog-01-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"770\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Algernon Pharma, 4DMedical, Poxel, SaNotize","description":"Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19. The company has..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Algernon Pharma, 4DMedical, Poxel, SaNotize","og_description":"Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19. The company has..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-05-26T14:11:43+00:00","article_modified_time":"2023-02-10T06:19:16+00:00","og_image":[{"width":770,"height":480,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/26194923\/blog-01-1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical","name":"Pharma News | Algernon Pharma, 4DMedical, Poxel, SaNotize","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/26194923\/blog-01-1.jpg","datePublished":"2020-05-26T14:11:43+00:00","dateModified":"2023-02-10T06:19:16+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Algernon Pharmaceuticals has announced the submission of an Investigational New Drug (IND) application of its drug, NP-120 for COVID-19. The company has..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-algernon-sanotize-poxel-4dmedical#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/26194923\/blog-01-1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/26194923\/blog-01-1.jpg","width":770,"height":480,"caption":"Recent-pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/05\/26194923\/blog-01-1-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">4DMedical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Algernon Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">COVID-19 News<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hepatitis c<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">NASH<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Non Alcoholic Steatohepatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Poxel<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Type 2 diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ulcerative Colitis Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">4DMedical<\/span>","<span class=\"advgb-post-tax-term\">Algernon Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">COVID-19<\/span>","<span class=\"advgb-post-tax-term\">COVID-19 News<\/span>","<span class=\"advgb-post-tax-term\">hepatitis c<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">NASH<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Non Alcoholic Steatohepatitis<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Poxel<\/span>","<span class=\"advgb-post-tax-term\">Type 2 diabetes<\/span>","<span class=\"advgb-post-tax-term\">Ulcerative Colitis Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on May 26, 2020","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on May 26, 2020 7:41 pm","modified":"Updated on Feb 10, 2023 11:49 am"},"featured_img_caption":"Recent-pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9425"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9425\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9430"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9425"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9425"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}